Biologics for pediatric psoriasis and atopic dermatitis

Thursday, January 21, 2021

In the news:

Pityriasis rosea carries few risks for pregnant women

Adjuvant nivolumab plus ipilimumab shows strong results in resected stage IV melanoma

* * *

Because psoriasis and atopic dermatitis (AD) can greatly affect quality of life in pediatric patients, the development of treatments with low-side effect profiles and less laboratory monitoring is essential. Vincent A. DeLeo, MD, talks to Amy S. Paller, MD, and Jennifer B. Scott, MD, about biologics approved for psoriasis and AD in the pediatric population. “Progressively, we’ve seen the newer biologics being more and more effective in both adults and in children, so we’re able to take some of the more effective ones and apply them to our children and adolescents with psoriasis ... We keep raising the bar in children as well as adults,” Dr. Paller reflects. They also discuss the advantages and pitfalls of biologics versus traditional systemic treatments as well as therapies on the horizon.


Downloadable PDF:

* * *

Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles)

Guests: Amy S. Paller, MD (department of dermatology and the department of pediatrics, Northwestern University, Chicago) and Jennifer B. Scott, MD (department of dermatology, Northwestern University)

Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Paller has been an investigator and/or consultant for numerous companies. Dr. Scott reports no conflict of interest.

Show notes by: Allegra Sparta, Melissa Sears

* * *

You can find more of our podcasts at

Email the show:

Interact with us on Twitter: @MDedgeDerm

Podcast Participants